A validated chiral chromatographic method for the enantiomeric separation of acalabrutinib.

Acalabrutinib is aided in the treatment of various cancers, which acts by inhibiting Bruton tyrosine kinase. Acalabrutinib belongs to the imidazopyrazine class consisting of a chiral carbon, resulting in two enantiomers. Currently, no methods exist for the separation and quantification of these enantiomers. A novel and selective enantiomeric chromatographic technique has been established to estimate the enantiomeric purity of acalabrutinib. Chiral separation was carried out on an immobilized amylose-based chiral stationary phase with methyl tert-butyl ether/ethanol/ethylenediamine (60:40:0.1% v/v) mixture as a mobile phase. The total runtime is 20 min, and the resolution (Rs ) between the enantiomers was more than 2.5. The detection and quantification thresholds for the R-enantiomer were 0.06 and 0.2 µg mL-1 , respectively, for a test concentration of acalabrutinib (1000 µg mL-1 ). The linearity of the technique for the R-enantiomer was excellent (R2 > 0.999) over the range from the limit of quantification to 0.3%. Recovery of the R-enantiomer was ranged from 95% to 102%, indicating the greater accuracy of the technique. For a 48-h research period, the drug was shown to be stable.

Inflammatory bowel disease.

Crohn disease and ulcerative colitis are the most common forms of inflammatory bowel disease (IBD) likely to be encountered in primary care. Patient-centered care is essential for positive outcomes, and should include long-term continuity with an empathetic primary care provider who can provide skillful coordination of the requisite multidisciplinary approach. Early suspicion of the diagnosis and referral to expert gastroenterologists for confirmation and medical management is essential. Coordinating interdisciplinary consultations, including colorectal surgeons, radiologists, stoma therapists, psychologists, and rheumatologists, in combination with comprehensive patient education, is key to decreasing overall morbidity, mortality, and health care costs associated with IBD.

Provider Link: facilitating healthcare providers' support of web-based smoking cessation efforts via secure e-mail.

Provider Link is a system designed to enhance the efficacy of a web-based intervention for smoking cessation by helping health care providers support their patients via e-mail. The system is designed to maintain confidentiality while allowing providers rapid access to patient data collected over the web. A trial of Provider Link is currently underway.